Home| Journals | Statistics Online Expert | About Us | Contact Us

    About this Journal  | Table of Contents

[Abstract] [PDF] [HTML] [Linked References]

International Journal of Recent Trends in Science and Technology, ISSN 2277-2812 E-ISSN: 2249-8109

Volume 16, Issue 1, Aug 2015 pp 61-65

Research Article

A comparative study of phosphate binders in patients of end stage kidney disease undergoing haemodialysis

Manjuprasad M S1, Padmaja Udaykumar2, Shreya Hegde3

1,3PG. Resident, 2Professor and HOD, Department of Pharmacology, A Block, Father Muller Medical College, Mangalore-575002, Karnataka, INDIA.

Introduction: Hyperphosphatemia is one of the complication in patients with chronic kidney disease on long term haemodialysis which will add on to the morbidity and mortality of the patient. This study was conducted in an attempt to compare the efficacy of phosphate binders prescribed to the patients of end stage kidney disease undergoing haemodialysis. It was a retrospective study in which medical records of patients with ESKD who received phosphate binders over past 2 years (2013 and 2014) were included in the study and divided into groups receiving sevelemer, calcium carbonate and calcium acetate and their baseline serum phosphate levels were compared with serum phosphate levels after 8weeks of treatment and found that at the end of 8th week the difference in control of phosphate levels in sevelemer group compared with control group was highly significant with a p value of 0.003. The difference in control of phosphate levels in the calcium carbonate group compared with control group also had a significant result with p value 0.039. There were no significant differences in calcium acetate and control group with respect to serum phosphate level difference at the end of 8th week. There were no statistically significant differences between individual groups. Conclusion: Our study confirms that phosphate binders significantly control the serum phosphate levels over a period of eight weeks treatment in ESKD patients on haemodialysis. However sevelemer was found to be more effective in controlling the serum phosphate levels but its high costs limits its use for the poor socioeconomic population.